GENUS ONCOLOGY - THE MUC1-C COMPANY
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target

Sitemap

Company
  • Mission
  • About Us
  • Genus Overview
  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Clinical and Research Partners
  • Contact
  • Sitemap

Why Target MUC1-C?

Clinical Trials
  • Summary
  • GO-203
  • Phase 2 AML Clinical Trial

The Science
  • Overview
  • MUC1 in Human Cancer: The Numbers
    • Breast Cancer
    • Non-Small Cell Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Esophagus Cancer
    • Gastric Cancer
    • Pancreatic Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Acute Myeloid Leukemia (AML)
    • Multiple Myeloma
  • MUC1 in Human Cancer: Overexpression
  • Target for Carcinoma Stem-like Cell
  • Target for Leukemia Stem Cell
  • MUC1-C is an Attractive Target for Reversing Immune Evasion​
  • Intellectual Property

Programs
  • The Pipeline
  • Targeting the Cytoplasmic Domain
  • Targeting the Extracellular Domain
  • Biomarker Program

News and Publications
  • News
  • Publications
    • Complete Listing
    • Role of MUC1-C in Signal Transduction
    • Role of MUC1-C in Epigenetic Regulation
    • Role of MUC1-C in Immune Evasion
    • MUC1 Vaccine
    • MUC1-C in Stem-like Cells
    • MUC1-C inhibitor formulated in nanoparticles
    • MUC1-C is synergistic with chemotherapeutic and targeted drugs
    • MUC1-C is a druggable target
Picture
sitemap.xml
File Size: 15 kb
File Type: xml
Download File

Company

About Us
Management
Board of Directors
​Contact
​
Sitemap

Science

MUC1-C
Why Target?
MUC1-C in Stem Cells
Publications

Programs

Targeting
Biomarker
Intellectual Property

Pipeline

Pipeline
​Clinical Trials

News

News
​Publications
© COPYRIGHT 2020 ALL RIGHTS RESERVED.
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target